Quinpramine for Parkinson's Disease (anti alpha-synuclein therapy)

VALUE PROPOSITION

Novel treatment mechanism: Potential disease modifying effect through inhibition of alpha-synuclein pathophysiology

Potential in other protein aggregation diseases e.g. Alzheimer's Disease, Amyotrophic Lateral Sclerosis

MODE OF ACTION

Quinpramine is a chimeric small molecule designed from the pharmacophores of the tricyclic antidepressant desipramine and the antimalarial drug quinacrine to provide maximal inhibitory effects on the amplification of misfolded proteins such as the Prion protein or alpha-synuclein. 

TARGET INDICATION RATIONALE

Parkinson’s Disease progression involves abnormal aggregation of normal brain proteins into deposits of insoluble irritant material. One protein involved in many cases is alpha synuclein. Preventing these deposits starting, or stopping them increasing in size, is one promising means of stopping progression of the disease. Quinpramine prevents proteins from misfolding and consequently formation of the insoluble deposits.

DEVELOPMENT STAGE

Preclinical Development, ca 1 year from IND

KEY DATA

Disease model (pilot): prevention of mortality in h-alpha-synuclein overexpressing mice